Eli Lilly and Company (NYSE:LLY) Stock Price Expected to Rise, Truist Financial Analyst Says

Eli Lilly and Company (NYSE:LLY) had its target price upped by analysts at Truist Financial from $1,038.00 to $1,182.00 in a report issued on Wednesday,MarketScreener reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price target would suggest a potential upside of 13.59% from the stock’s current price.

Several other brokerages have also commented on LLY. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research note on Tuesday. Guggenheim reissued a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 16th. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. Finally, Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,027.95.

Eli Lilly and Company Stock Up 1.0%

NYSE:LLY opened at $1,040.55 on Wednesday. The firm’s 50 day simple moving average is $838.20 and its 200 day simple moving average is $782.36. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market cap of $983.72 billion, a PE ratio of 68.11, a P/E/G ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,040.72.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter last year, the firm posted $1.18 earnings per share. The company’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors have recently bought and sold shares of the company. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at $27,000. Sumitomo Mitsui Financial Group Inc. acquired a new stake in shares of Eli Lilly and Company during the second quarter worth approximately $27,000. Evolution Wealth Management Inc. bought a new position in Eli Lilly and Company during the second quarter worth $29,000. Steph & Co. boosted its holdings in shares of Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after acquiring an additional 29 shares during the period. Finally, Financial Gravity Companies Inc. acquired a new position in shares of Eli Lilly and Company during the second quarter valued at $31,000. 82.53% of the stock is owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.